KSD-101 for EBV-related blood cancers that have come back
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new study treatment called KSD-101 for blood cancers linked to the Epstein-Barr virus (EBV) that have come back or not responded to other treatments. The goal is to see if it is safe and effective for people with these types of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 2 and 70 years old (older may be allowed with the doctor's approval).
- You have a blood cancer that is positive for EBV (the virus that causes mono) and has come back or not responded to treatment.
- You have at least one measurable tumor (larger than a certain size) that can be seen on scans.
- You are in fairly good physical shape, able to do light activities (ECOG score 0-1).
- You are healthy enough to undergo a blood collection procedure called leukapheresis (like giving blood cells).
- Your organ function (liver, kidney, heart, lungs, blood counts) is within a range that makes it safe to join the trial.
- You agree to use effective contraception (not hormonal) for the duration of the study and for 6 months after your last dose, if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies KSD-101 (a vaccine treatment) for people whose blood cancers are linked to EBV and who have not responded or have relapsed after standard treatment. It may help your immune system better control the cancer, especially when other options have already been tried.
This study tests a new injection called KSV01 for people with a type of lymphoma (DLBCL) that has returned or not responded to previous treatments. The goal is to see if it can help shrink tumors or stop the disease from getting worse.
This trial tests an experimental vaccine called KSD-101 for people with blood cancers or lymphomas linked to the Epstein-Barr virus. The vaccine aims to help your immune system fight the cancer or prevent it from coming back.
This trial tests a new cell therapy called KSD-101 for nasopharyngeal cancer that has not responded to standard treatments. The therapy is injected into your lymph nodes and works by boosting your immune system to fight the cancer.
This trial tests a new treatment (KSD-101) for nasopharyngeal cancer that has not responded to standard therapies. It aims to see if this treatment can help when other options have failed.
This trial tests a new drug called VK-2019 for people whose EBV-positive diffuse large B-cell lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this drug can shrink tumors and help control the cancer.
Hear when a new Relapsed or Refractory EBV-associated Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.